Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema
نویسندگان
چکیده
Maurizio Paciaroni, MD; Giancarlo Agnelli, MD; Valeria Caso, MD, PhD; Georgios Tsivgoulis, MD; Karen L. Furie, MD; Prasanna Tadi, MD; Cecilia Becattini, MD; Nicola Falocci, PhD; Marialuisa Zedde, MD; Azmil H. Abdul-Rahim, MD; Kennedy R. Lees, MD; Andrea Alberti, MD; Michele Venti, MD, PhD; Monica Acciarresi, MD; Cataldo D’Amore, MD; Maria Giulia Mosconi, MD; Ludovica Anna Cimini, MD; Antonio Procopio, MD; Paolo Bovi, MD; Monica Carletti, MD; Alberto Rigatelli, MD; Manuel Cappellari, MD; Jukka Putaala, MD; Liisa Tomppo, MD, PhD; Turgut Tatlisumak, MD; Fabio Bandini, MD; Simona Marcheselli, MD; Alessandro Pezzini, MD; Loris Poli, MD; Alessandro Padovani, MD, PhD; Luca Masotti, MD; Vieri Vannucchi, MD; Sung-Il Sohn, MD, PhD; Gianni Lorenzini, MD; Rossana Tassi, MD; Francesca Guideri, MD; Maurizio Acampa, MD; Giuseppe Martini, MD; George Ntaios, MD; Efstathia Karagkiozi, MD; George Athanasakis, MD; Kostantinos Makaritsis, MD; Kostantinos Vadikolias, MD; Chrysoula Liantinioti, MD; Maria Chondrogianni, MD; Nicola Mumoli, MD; Domenico Consoli, MD; Franco Galati, MD; Simona Sacco, MD; Antonio Carolei, MD; Cindy Tiseo, MD; Francesco Corea, MD, PhD; Walter Ageno, MD; Marta Bellesini, MD; Giovanna Colombo, MD; Giorgio Silvestrelli, MD, PhD; Alfonso Ciccone, MD; Umberto Scoditti, MD; Licia Denti, MD; Michelangelo Mancuso, MD; Miriam Maccarrone, MD; Giovanni Orlandi, MD; Nicola Giannini, MD; Gino Gialdini, MD; Tiziana Tassinari, MD; Maria Luisa De Lodovici, MD; Giorgio Bono, MD; Christina Rueckert, MD; Antonio Baldi, MD; Sebastiano D’Anna, MD; Danilo Toni, MD, PhD; Federica Letteri, MD; Martina Giuntini, MD; Enrico Maria Lotti, MD; Yuriy Flomin, MD; Alessio Pieroni, MD; Odysseas Kargiotis, MD; Theodore Karapanayiotides, MD, PhD; Serena Monaco, MD; Mario Maimone Baronello, MD; Laszló Csiba, MD; Lilla Szabó, MD; Alberto Chiti, MD; Elisa Giorli, MD; Massimo Del Sette, MD; Davide Imberti, MD; Dorjan Zabzuni, MD; Boris Doronin, MD; Vera Volodina, MD; Patrik Michel, PD-MER; Peter Vanacker, MD; Kristian Barlinn, MD; Lars-Peder Pallesen, MD; Jessica Kepplinger, MD; Ulf Bodechtel, MD; Johannes Gerber, MD; Dirk Deleu, MD, PhD; Gayane Melikyan, MD; Faisal Ibrahim, MD; Naveed Akhtar, MD; Vanessa Gourbali, MD; Shadi Yaghi, MD
منابع مشابه
Antithrombotic therapy in anticoagulated patients with atrial fibrillation presenting with acute coronary syndromes and/or undergoing percutaneous coronary intervention/stenting.
The management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary inter vention/stenting cannot be done according to a regimented common protocol, and stroke and bleeding risk stratification schema should be employed to individualize treatment options. A delicate balance is needed between the prevention of th...
متن کاملCan We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case
OBJECTIVES To construct and validate a prediction model for individual combined benefit and harm outcomes (stroke with no major bleeding, major bleeding with no stroke, neither event, or both) in patients with atrial fibrillation (AF) with and without warfarin therapy. METHODS Using the Kaiser Permanente Colorado databases, we included patients newly diagnosed with AF between January 1, 2005 ...
متن کاملThe balance between stroke prevention and bleeding risk in atrial fibrillation: a delicate balance revisited.
See related article, pages 1482–1486. Although atrial fibrillation (AF) is well recognized to confer a risk of stroke, this risk is not homogeneous. Oral anticoagulation (OAC) with warfarin is highly beneficial, but such therapy is inconvenient and carries a risk of bleeding. Thus, stroke risk stratification schemes have been devised to identify “high risk” AF patients for whom the absolute ben...
متن کاملAntithrombotic treatment and atrial fibrillation
Non-rheumatic atrial fibrillation increases the risk of stroke by a factor of five and is present in about 15% of patients with acute stroke.' 2 Its prevalence in the general population increases with age-from 050/o at 50-59 to 8-8% at 80-89.2 The risk of someone with atrial fibrillation having a stroke is about 5% a year and increases with age, blood pressure, and other evidence of heart disea...
متن کاملIndependent Effect of Digoxin in Preventing Atrial Fibrillation in High Risk Patients after CABG Surgery
Background: Atrial fibrillation (AF) is one of the most common arrhythmias after coronary artery bypass graft (CABG) surgery. AF can result in hemodynamic instability, thromboembolic events, increase the perioperative myocardial infarction, congestive heart failure, stroke, more length of hospital stay (LOHS) and cost of treatment. The aim of this study was to evaluate the independent effect of...
متن کاملHypercoagulability and haemodynamic abnormalities in atrial fibrillation.
Non-valvar atrial fibrillation confers a substantial risk for stroke and thromboembolism which is estimated to be between 4-5% and 12% per year depending on associated risk factors.'2 Recent studies have established the value of warfarin as thromboprophylaxis in atrial fibrillation; however, this treatment carries with it the inconvenience of regular monitoring of anticoagulation intensity and ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017